2017 American Transplant Congress
Evaluation of Low Dose Valganciclovir for the Prevention of Cytomegalovirus in Liver Transplant Recipients.
BACKGROUND: Cytomegalovirus (CMV) causes significant morbidity and mortality following orthotopic liver transplantation (OLT). Valganciclovir (VGCV) is used to prevent CMV, but at labeled doses can…2017 American Transplant Congress
CMV-Infected Kidney Grafts Drive the Expansion of Blood-Born CMV-Specific T-Cells Restricted by Shared HLA Molecules Through Presentation on Donor's Cells.
Background. Cytomegalovirus specific immune response is crucial to control CMV infection in kidney transplant recipients (KTR), in whom recipient CMV can reactivated (R+) and donor…2017 American Transplant Congress
Evaluation of Immunological States of Patients with Cytomegalovirus Infection After Kidney Transplantation.
Department of Gastroenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan
Background: Generally, it is thought that strong immunosuppression causes cytomegalovirus (CMV) infection after kidney transplantation (KT); thus, physicians often reduce the dose of the immunosuppressant…2017 American Transplant Congress
In the Modern Era, Cytomegalovirus Does Not Appear to Increase Intimal Thickening After Heart Transplantation.
Cedars-Sinai Heart Institute, Los Angeles
Background: Cytomegalovirus (CMV) has been associated with the subsequent development of cardiac allograft vasculopathy (CAV) after heart transplantation. In the more recent era, CMV has…2017 American Transplant Congress
Acute Mouse CMV Infection Abrogates Transplant Tolerance by Modulating Myeloid Cell Differentiation and Function: A Possible Role for Transcription Factor RORγt.
Cytomegalovirus (CMV) infection has long been associated with graft-dysfunction and rejection in transplant-recipients. Nevertheless, precise understanding of underlying molecular mechanisms remains unclear. Here, we investigated…2017 American Transplant Congress
Eight Years of Low-Dose Valganciclovir; Evaluating the Incidence and Risk Factors of CMV in Kidney Transplant Recipients.
Kidney Transplant, Brigham and Women's Hostpial, Boston, MA
Introduction: Cytomegalovirus (CMV) remains one the most clinically relevant and frequent post-transplant infections. Despite the availability of effective antiviral drugs, CMV continues to be of…2017 American Transplant Congress
Reducing the Early Readmission Rates in Kidney Transplantation.
Nephrology Division, Hospital do Rim Foudation, São Paulo, Brazil
Background: 30-day hospital readmission rate is a well-accepted quality metric and a predictor of mortality among kidney transplant recipients.Objective: The aim of this study is…2017 American Transplant Congress
IVIg+Rituximab Desensitization (DES) Combined with Alemtuzumab (ATZ) Induction Does Not Increase Risk for Viral Infections (VIs) and Associated Complications in HLA-Sensitized (HS) Kidney Transplant Patients (KTx Pts).
Background: VIs represent significant morbidity factors in KTx pts. DES followed by KTx with ATZ induction increased successful Tx rates in HS pts, but may…2017 American Transplant Congress
Cytomegalovirus Viral Load: Characterization of Results from Clinical Specimens.
Viracor Eurofins, Lees Summit, MO
Cytomegalovirus (CMV) infection, a frequent complication affecting solid organ and hematopoietic stem cell transplant recipients, is commonly diagnosed and monitored by quantitative PCR (qPCR) methods.…2017 American Transplant Congress
Association of BK and CMV Viremia with Pancreas Allograft Survival Among Adults Receiving Simultaneous Pancreas and Kidney Transplant: The Wisconsin Allograft Recipient Database (WisARD).
Department of Medicine, University of Wisconsin, Madison, WI
Knowing impact of BKV viremia and CMV infection on pancreas allograft outcome post Simultaneous Pancreas and Kidney transplant (SPK) may improve allograft long-term survival and…
- « Previous Page
- 1
- …
- 20
- 21
- 22
- 23
- 24
- …
- 33
- Next Page »